3D Medicines Inc. (1244.HK)

5.960 +0.070 (+1.19%) At close: 04:08PM HKT

3D Medicines Inc.

No. 3 and No. 5, Laiyang Road
Qingdao 266000
China

https://www.3d-medicines.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 198

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Zhaolong Gong M.D., Ph.D.	Key Founder, CEO & Executive Chairman	1.98M	N/A	1965
Ms. Jing Zhang	Chief Financial Officer	N/A	N/A	1974
Dr. Shen Xiao	Chief Strategy Officer & Chief Medical Officer	N/A	N/A	1966
Ms. Fang Xia	Head of Regulatory Affairs, VP & Joint Company Secretary	N/A	N/A	1981
Ms. Ching Yi Li	Joint Company Secretary	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the Mainland China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in Phase II clinical trials G/GEJ and TMB-H advanced cancer, EC, HCC,CRC, NSCLC, microsatellite satble CRC, and dMMR advanced sold tumors. In addition, it provides products which is in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for cancer pain/osteoarthritis and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor; and 3D057, 3D124, 3D060, and 3D062 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

Corporate Governance

3D Medicines Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.